These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7222106)

  • 21. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.
    Berman JS; Hiley CR; Wilson AC
    Br J Pharmacol; 1983 Mar; 78(3):533-41. PubMed ID: 6839062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
    Petit D; Bonnefis MT; Rey C; Infante R
    Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot studies evaluating the nongenotoxic rodent carcinogens phenobarbital and clofibrate in the rat Pig-a assay.
    Ji Z; Settivari RS; LeBaron MJ
    Environ Mol Mutagen; 2019 Jan; 60(1):42-46. PubMed ID: 30338550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in the thyroids of rats treated for long periods with di-(2-ethylhexyl) phthalate or with hypolipidaemic agents.
    Price SC; Chescoe D; Grasso P; Wright M; Hinton RH
    Toxicol Lett; 1988 Jan; 40(1):37-46. PubMed ID: 3341048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetaben versus clofibrate: comparison of toxicity and peroxisome proliferation in rats.
    Fort FL; Stein HH; Langenberg K; Lewkowski JP; Heyman IA; Kesterson JW
    Toxicology; 1983 Nov; 28(4):305-11. PubMed ID: 6606240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.
    Bronfman M; Amigo L; Morales MN
    Biochem J; 1986 Nov; 239(3):781-4. PubMed ID: 3827829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo covalent binding of chemicals to DNA as a short-term test for carcinogenicity.
    Lutz WK; Schlatter C
    Arch Toxicol Suppl; 1979; (2):411-5. PubMed ID: 288355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients.
    Blümcke S; Schwartzkopff W; Lobeck H; Edmondson NA; Prentice DE; Blane GF
    Atherosclerosis; 1983 Jan; 46(1):105-16. PubMed ID: 6838687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog.
    Weil A; Caldwell J; Strolin-Benedetti M
    Drug Metab Dispos; 1988; 16(2):302-9. PubMed ID: 2898351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of the potential for binding of Di(2-ethylhexyl) phthalate (DEHP) and Di(2-ethylhexyl) adipate (DEHA) to liver DNA in vivo.
    von Däniken A; Lutz WK; Jäckh R; Schlatter C
    Toxicol Appl Pharmacol; 1984 May; 73(3):373-87. PubMed ID: 6719458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The slow induction of resistant hepatocytes during initiation of hepatocarcinogenesis by the nongenotoxic carcinogen clofibrate.
    Nagai MK; Farber E
    Exp Mol Pathol; 1999 Dec; 67(3):144-9. PubMed ID: 10600397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
    Malátková P; Kanavi M; Nobilis M; Wsól V
    Chem Biol Interact; 2016 Oct; 258():153-8. PubMed ID: 27599626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The fate of clofibrate in the perfused rat liver.
    Laker ME; Mayes PA
    Biomedicine; 1978 May; 29(3):88-90. PubMed ID: 687751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives.
    Blane GF
    Am J Med; 1987 Nov; 83(5B):26-36. PubMed ID: 3318450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of dehydroepiandrosterone and clofibrate on the binding of 7,12-dimethyl benz(a)anthracene to hepatic DNA in vivo--a preliminary study.
    Prasanna HR; Hart RW; Magee PN
    Drug Chem Toxicol; 1989; 12(3-4):327-35. PubMed ID: 2534380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver.
    Lalwani ND; Alvares K; Reddy MK; Reddy MN; Parikh I; Reddy JK
    Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5242-6. PubMed ID: 3474650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro.
    Gupta RC; Goel SK; Earley K; Singh B; Reddy JK
    Carcinogenesis; 1985 Jun; 6(6):933-6. PubMed ID: 4006083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
    Bercu JP; Jolly RA; Flagella KM; Baker TK; Romero P; Stevens JL
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):369-81. PubMed ID: 20801182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.
    Gonzalez FJ; Peters JM; Cattley RC
    J Natl Cancer Inst; 1998 Nov; 90(22):1702-9. PubMed ID: 9827524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family.
    Alvares K; Carrillo A; Yuan PM; Kawano H; Morimoto RI; Reddy JK
    Proc Natl Acad Sci U S A; 1990 Jul; 87(14):5293-7. PubMed ID: 2371272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.